The European pharmaceutical giant Pfizer has a huge presence in Europe, which means it has to compete with big names like CVS Caremark and HealthPartners.
But it’s also worth noting that the US and Europe are often the main sources of Pfizer’s growth.
This is the company’s first foray into China, and Pfizer isn’t the only pharmaceutical company hoping to make a splash in China.
Here’s how it works: China’s drug market is extremely fragmented.
The US and European marketplaces are very similar, with big players like Cephalon and Merck controlling large segments of the market.
But China has a much smaller and smaller number of competitors, making it much harder for big players to get into China’s lucrative market.
China has been a hotbed of pharmaceutical innovation for decades, and this year, the country has seen a surge in the number of Chinese companies opening up.
Pfizer is one of those companies, and it recently set up a lab in China to try to help Chinese pharmaceutical companies get into the US market.
Here are some of the company´s key achievements: Pfizer, which is based in Dublin, Ireland, has made some big acquisitions in China over the past year.
Last year, it bought Pfizer UK for $4.7 billion, and now it’s making an even bigger splash.
Last October, it acquired a huge chunk of China´s pharma market, the Biomed Biotech Alliance.
In November, Pfizer announced it was building a factory in China and opening a lab to help drugmakers get into that market.
And it plans to open a manufacturing facility in the Chinese city of Chengdu in 2018, in partnership with local Chinese pharmaceutical giant Huaxi Biotechnology.
Pfizers plans to be in China for the next five years, with the factory in the city of Shenzhen.
Its goal is to eventually produce up to 40 million tablets per year, which will represent roughly one in five tablets sold in China, according to Pfizer.
China is also home to a huge number of specialty pharmaceutical companies, like the Chinese brand BioMedic.
This year, BioMedics announced it would expand its China operations, adding to the number in the country.
These companies make medications that target specific diseases, and have helped Pfizer to build a strong presence in the nation.
Pfizons growth in China comes as Pfizer continues to invest heavily in China as well.
It invested $30 billion in China last year, and the company is now looking to grow its China business by an even larger $300 billion.
In 2018, Pfizonia reported its first quarterly profit for nearly two decades.
It’s also investing heavily in research and development in China this year.
Pfitzonia also plans to expand its product line in China into other countries.
The company plans to invest $20 billion in Chinese research and manufacturing facilities, which it said will create thousands of jobs over the next few years.
Pfizon is also expanding its business in the UK.
The pharmaceutical giant bought UK drugmaker Sainsbury’s last year for $10 billion, which has led to an expansion in China in the years since.
Sainsburys is now one of the world’s largest drugmakers, and its brands include Rovio, Mylan, and Mylan-branded medicines.
It has invested heavily in its Chinese research labs.
In the past two years, Pfizon has also started buying up the UK’s pharmaceutical company, AstraZeneca, which makes generic versions of generic versions Pfizer sells in Europe.
Pfithias investment in the British pharmaceutical company is part of a larger strategy to grow sales in China beyond its own research labs, and to compete more directly with Chinese rivals.
In 2020, Pfithia said it would invest an additional $5 billion in research facilities in China by 2022.
And the pharmaceutical giant plans to buy up to 10 million patents per year in China between 2020 and 2021, the first year of the deal.
This comes as China has seen an explosion in new medications in the past decade, and new drugs that target the same disease have grown significantly.
In 2016, Pfitzon made a deal with Chinese pharmaceutical firm Huaxia Biotech to sell up to 1 million of the generic versions it sells in the US.
Pfiths growth in the China market comes at a critical time for Pfizer and other pharmaceutical companies.
The country is undergoing a huge transition to a more integrated economy, with China becoming a more attractive source of growth for pharmaceutical companies around the world.
China’s economy is expected to grow by nearly $30 trillion by 2020, and there are fears that this will make the country more attractive for pharmaceuticals companies to invest in.
According to Pfithies research, the growth in Chinese pharmaceuticals is likely to be driven by more than a one-off phenomenon.
China may see a surge of new medicines in the next year or two, and some of them will be targeted specifically at